About UsOur Partners

Physiomics plc works with partners from both small and large pharmaceutical and biotechnology companies. These include Merck Sharpe & Dohme Corp., Eli Lilly, Merck Serono, Sareum, Institute of Cancer Research, Cancer Research Technology, Cyclacel Pharmaceutical and ValiRx.

Our technology has conferred many benefits to our partners:

Merck Sharp & Dohme Corp.Merck & Co., known as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a leading research-driven healthcare company, and a top 5 pharmaceutical company. MSD has disclosed that it is a customer of Physiomics in a scientific paper published in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process.

Merck SeronoAfter having worked on a number of pre-clinical projects for several years, Physiomics has signed in 2015 its first contract for developing Virtual Tumour Clinical with Merck Serono. Physiomics scientists will be working closely with Merck Serono scientists to develop and calibrate a model that can predict optimal combination partners for both marketed and pipeline drugs.

Eli LillyPhysiomics has entered a master service agreement with Lilly in 2007, and since has provided support to Lilly's oncology program on a handful of projects. It has also licensed customized versions of its ModelPlayer to Lilly, allowing them to perform their own simulations of anticancer agents using Physiomics’ models.

Pharmacometrics logoIn 2011, Physiomics and Phramacometrics have entered into an agreement to develop a new anti-cancer drug regimen and combination database. This database will be ultimately marketed to clinicians and researchers in oncology, as well as used to supplement and enhance Physiomics' service.

SareumIn 2010, Physiomics has entered into a collaboration with Sareum, in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).

Swansea University Prifysgol AbertaweIn 2007, Physiomics and the Institute of Life Science at Swansea University (ILS) have entered into a collaborative research program. The goal of this collaboration was to validate Physiomics models and technology on supercomputers, such as the High Performance Computer “Blue C” available at the ILS, one of the most powerful computers in the world dedicated to Life Science and result of a collaboration between the University, the Welsh Assembly Government and computer giant IBM. This has reinforced Physiomics’ modelling framework and helped to address the ever increasing computing requirements in the field of System Biology.

ValirxOur apoptosis model technology has supported both “no-go” and “go” decisions for therapeutic targets. George Morris, Chief Development Officer of ValiRx, said: "Physiomics service and technology is absolutely superb, we (ValiRx) have just had some work carried out and it has saved us very significant amounts of development money and time. This is the first time the research has been done this way…"

TempoWe are developing our technology with both industrial and academic partners across the European Union: as part of the TEMPO project (October 2006 – December 2009) we have developed combined pharmacokinetic-pharmacodynamic models of cancer processes in order to determine optimal chronotherapeutic scheduling for cell cycle inhibitors.

Bayer Technology ServicesWe have also been working with other industrial partners to develop and enhance our technological capability. In 2004, Physiomics entered into a strategic alliance with Bayer Technology Services GmbH (BTS) to integrate PK-Sim® with its novel biological simulations.

If you are interested in knowing more about Physiomics and how we might deliver benefit to your research effort, please contact us.